Carles obtained a BSs/MSc degree in biology (first class honors) from the Autonomous University of Barcelona and also a PhD degree in cellular biology from the same University, working at the Council of Science Research (CSIC). He has additional business training at ESADE business school and other business programs.

After his career in CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering Cancer Center in New York (1990-1992), he held senior positions at  Almirall, SA (1992-2003) as Manager and Head of Business Development and Licensing and Lacer, SA (2005-2007) as Director, Business Development and Licensing.
 

Carles has also 4 years experience in biotech venture capital and business angels associations and has also been collaborating with government innovation agencies. Between 2004 and 2005 he was Director, Biotech Investments at the seed venture capital firm Barcelona Emprèn, SCRSA. During 2008-2009 he collaborated with agencies of the Government of Catalonia as Director, Technology Transfer and Valorization and as Managing Director, Investment and Enterprise Growth. He had under his responsibility the seed venture capital company Invertec, SA and the entrepreneurship finance programs Genesis Capital and Concept Capital. Since July 2009 he also advises Keiretsu Forum Barcelona in biotech investments.
 

In 2009 Carles cofounded Ability Pharmaceuticals, SL to become its Chief Executive Officer in September 2009

Héctor obtained his BSc degree in Biology in 2005 and his Ph.D. in Biology in 2010 at University of Alicante. In 2006 he moved to University of Texas Southwestern Medical Center in Dallas (EEUU), to start his career developing novel therapeutic antibodies in murine models of human autoimmune diseases and under the supervision of Dr. Sally E. Ward, a worldwide outstanding investigator in the field of autoimmune diseases and cancer.

After obtaining his Ph.D., he combined two postdoctoral grants in Barcelona (Metastasis and Transformation group in Bellvitge Biomedical Research Center - IDIBELL) and in Valencia (Autoimmune Pathology Lab in Principe Felipe Research Center). In between, he worked as a coordinator of an animal experimentation laboratory from a private company, developing novel therapeutic agents for autoimmune diseases and cancer.

During the 10 years of experience accumulated, animal research has characterized most of his work, accumulating large experience working with a large panel of murine models of different autoimmune diseases such as Multiple Sclerosis or Rheumatoid Arthritis, and in cancer, including the “Patient Derived OrthoXenograft” technique. His work always focused in understanding the molecular pathophysiological mechanisms leading to autoimmunity and cancer development, investigating mechanism of action of newly developed molecules to treat such diseases. He has collaborated in the publication of several articles in peer reviewed journals, abstracts in scientific meetings and patents.

In 2015 Héctor joined Ability Pharmaceuticals SL as a Director of Biological Research.

David completed his degree in Chemical Engineering at Worcester Polytechnic Institute. He holds a Healthcare Finance certificate from MITx.
 

David began his career at Shire Pharmaceuticals working in manufacturing and then as a process development engineer. From there, he moved into life science consulting with Longfellow Associates where he led projects and at times managed a team of consultants. Later, David joined AptaTargets where he served as the company’s CBO responsible for the company’s partnering initiatives. Throughout his career David has supported and led many life science transactions with assets ranging across many indications and stages.
 

David joined AbilityPharma in July 2024 as the Chief Business Officer to lead partnering and support some of the company’s strategic initiatives.

Petr obtained his Bachelor’s and Master’s degrees in Finance from the Prague University of Economics and Business and is currently pursuing an Executive MBA at ESADE Business School in Barcelona.

 

Before joining Ability Pharmaceuticals, he held various financial and general management roles, including Finance Director, Managing Director, and Interim General Manager, at several companies in the Czech Republic. During this time, he successfully led company expansions, executed strategic investments, built and managed teams, tackled transformation challenges, and oversaw complex business transitions. He also managed strategic M&A activities, including comprehensive due diligence and post-acquisition integration processes.

 

After relocating to Spain, Petr worked for a strategic consulting and financial advisory firm specializing in the Life Sciences sector, where he served as Head of the Life Sciences Business Unit and Head of Operations.

 

In 2024, Petr joined Ability Pharmaceuticals as Chief Financial Officer (CFO).

Vanessa obtained a degree in economics (BEc/MEc) at the Pompeu Fabra University of Barcelona. She specialized in business administration.
 

Vanessa collaborates with Ability Pharmaceuticals since 2010. Prior to joining the company, for 2 years she was the Chief Financial Officer of Sevibe Cells, a health services company specializing in the preservation of stem cells derived from umbilical cords.